Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00478361
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:59.643980+00:00
Published At
2020-10-09T00:00:00+00:00
Record Updated At
2020-10-09
Results Posted At
2020-10-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Distal Urethral Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Proximal Urethral Cancer", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter", "Stage III Bladder Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder", "Urethral Cancer Associated With Invasive Bladder Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-10-09"
protocolSection.identificationModule.nctId
"NCT00478361"
protocolSection.identificationModule.officialTitle
"A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-10-09"

Study condition terms

  • Distal Urethral Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter (protocolSection.conditionsModule.conditions)
  • Proximal Urethral Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter (protocolSection.conditionsModule.conditions)
  • Recurrent Urethral Cancer (protocolSection.conditionsModule.conditions)
  • Regional Transitional Cell Cancer of the Renal Pelvis and Ureter (protocolSection.conditionsModule.conditions)
  • Stage III Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Transitional Cell Carcinoma of the Bladder (protocolSection.conditionsModule.conditions)
  • Urethral Cancer Associated With Invasive Bladder Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.